All posts by: Michael Zand

About Michael Zand

AveXis Expands Clinical Testing of Gene Therapy, AVXS-101, to Include Milder SMA Types – SMA News Today

Continue reading

2018-01-19 NEWS

SMA News Today

AveXis Expands Clinical Testing of Gene Therapy, AVXS-101, to Include Milder SMA Types
SMA News Today
AveXis plans to launch clinical trials of its gene therapy AVXS-101 in a wider range of spinal muscular atrophy (SMA) patients — mirroring the company’s belief that the treatment may also benefit those with milder forms of the disease. The planned
Insider Selling: AveXis Inc (AVXS) Insider Sells 15000 Shares of StockThe Ledger Gazette
AveXis Inc. (AVXS) Soars 5.05% on January 18Equities.com
AveXis Inc (AVXS) VP James J. Litalien Sells 5000 SharesDispatch Tribunal
The Lincolnian Online –TrueBlueTribune
all 26 news articles »
Continue reading

2018-01-19 NEWS

The European Patent Office Revokes the Broad Institute’s CRISPR Patents
Labiotech.eu (blog)
The Broad Institute has been stripped of the first of its CRISPR/Cas9 patents by the European Patent Office due to previous publications outdating its work. CRISPR/Cas9 has been hailed as the ‘scientific discovery of the century’ due to its capacity to